- Algernon Pharmaceuticals (AGN) has been added to the Horizons Psychedelic Stock Index ETF (PSYK)
- The PSYK offers direct exposure to North American publicly listed securities in the psychedelics industry
- Algernon recently announced that it had established a clinical research program for the treatment of stroke focused on AP-188, a known psychedelic compound
- Algernon is a clinical-stage pharmaceutical development company
- Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.315 per share
Algernon Pharmaceuticals (AGN) has been added to the Horizons Psychedelic Stock Index ETF (PSYK).
The PSYK is the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities in the psychedelics industry.
The underlying index is the North American Psychedelic Stock Index, which is a proprietary index owned and operated by Horizons ETFs, and Solactive AG is the independent calculation agent for the index.
“On February 1st, 2021, Algernon announced that it had established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
“Being added to the PSYK is a reflection of the important work Algernon has undertaken with its DMT stroke research program and will help bring a further level of awareness to the company among a wide range of investors.”
Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.315 per share.
